Evidence map›Paper›PMID 33092070›Full record

SynthesisViruses2020

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade.

Brigette N Corder, Brianna L Bullard, Gregory A Poland, Eric A Weaver

Abstract readSystematic Review
In one paragraph

Synthesis in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Article
  3. Mapping climate change-driven epidemics.Frontiers in epidemiology · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Update on Influenza Vaccines: Needs and Progress.The journal of allergy and clinical immunology. In practice · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brigette N CorderSchool of Biological Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, 4240 Fair Street, Lincoln, NE 68503, USA.
Brianna L BullardSchool of Biological Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, 4240 Fair Street, Lincoln, NE 68503, USA.ORCID 0000-0002-6702-0079
Gregory A PolandMayo Vaccine Research Group, General Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Eric A WeaverSchool of Biological Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, 4240 Fair Street, Lincoln, NE 68503, USA.ORCID 0000-0002-5029-0662

Funding

Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized AntigensR01AI147109 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI MCCORMICK, ALISON ANNE, WEAVER, ERIC A · 2020 to 2024
$3.2M
Comparative Virology Research Training ProgramT32AI125207 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WEAVER, ERIC A · 2016 to 2020
$844k
NIAID NIH HHS R01 AI147109NIAID NIH HHS T32 AI125207
6 · The paper itself

Abstract

On average, there are 3-5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains. Therefore, the development of a universal influenza vaccine is a top priority for the NIH. Here, we report a comprehensive summary of all universal influenza vaccines that were tested in clinical trials during the 2010-2019 decade. Of the 1597 studies found, 69 eligible clinical trials, which investigated 27 vaccines, were included in this review. Information from each trial was compiled for vaccine target, vaccine platform, adjuvant inclusion, clinical trial phase, and results. As we look forward, there are currently three vaccines in phase III clinical trials which could provide significant improvement over seasonal influenza vaccines. This systematic review of universal influenza vaccine clinical trials during the 2010-2019 decade provides an update on the progress towards an improved influenza vaccine.

Indexed as

Clinical Trials as TopicInfluenza, HumanInfluenza VaccinesAdjuvants, ImmunologicAnimalsAntibodies, ViralDrug Delivery SystemsHumansOrthomyxoviridae InfectionsAdjuvants, ImmunologicAntibodies, ViralInfluenza Vaccinesadjuvantclinical trialsinfluenzainfluenza vaccineuniversal influenza vaccinevaccine platformvaccine target

Identifiers

PMID33092070
PMCPMC7589362

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.